Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REP 2139-Mg and REP 2165-Mg in Chronic Hepatitis B
NCT02565719Phase 2Completed
- Sponsor
- Replicor Inc.
- Start
- Mar 2016
- Primary completion
- May 2019
- Modality
- Antisense DNA, Polymer-based Nanoparticles, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of REP 2139-Mg, REP 2165-Mg in Chronic Hepatitis B (CHB), sponsored by Replicor Inc.. Started Mar 2016; status: completed.
02
Drugs
REP 2139-MgREP 2165-Mg
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02565719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565719.